Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone475-230-2596
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.13 billion
Profitability
Miscellaneous
Employees2,656
Next Earnings Date10/23/2019 (Estimated)
OptionableOptionable
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Wednesday, July, 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.13 by $0.51. The biopharmaceutical company earned $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. Alexion Pharmaceuticals's revenue for the quarter was up 15.1% on a year-over-year basis. During the same quarter last year, the company earned $2.07 earnings per share. View Alexion Pharmaceuticals' Earnings History.
When is Alexion Pharmaceuticals' next earnings date?
What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?
Alexion Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, July, 24th. The company provided earnings per share (EPS) guidance of $9.65-9.85 for the period, compared to the Thomson Reuters consensus estimate of $9.44. The company issued revenue guidance of $4.75-4.8 billion, compared to the consensus revenue estimate of $4.78 billion.
What price target have analysts set for ALXN?
15 Wall Street analysts have issued 12 month price targets for Alexion Pharmaceuticals' stock. Their forecasts range from $135.00 to $186.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $164.0667 in the next year. This suggests a possible upside of 32.9% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.
What is the consensus analysts' recommendation for Alexion Pharmaceuticals?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.
Has Alexion Pharmaceuticals been receiving favorable news coverage?
News headlines about ALXN stock have been trending positive on Friday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Alexion Pharmaceuticals.
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Zoetis (ZTS), Shire (SHPG), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Commonwealth Bank of Australia (CSLLY), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY) and Takeda Pharmaceutical (TKPYY).
What other stocks do shareholders of Alexion Pharmaceuticals own?
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the folowing people:
- Dr. Ludwig N. Hantson, CEO & Director (Age 56)
- Mr. Paul J. Clancy, Exec. VP & CFO (Age 57)
- Ms. Anne-Marie Law, Exec. VP and Chief Patient & Employee Experience Officer (Age 52)
- Mr. Brian M. Goff, Exec. VP & Chief Commercial Officer (Age 50)
- Dr. John J. Orloff, Exec. VP and Head of R&D (Age 62)
Who are Alexion Pharmaceuticals' major shareholders?
Alexion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.43%), BlackRock Inc. (7.24%), Price T Rowe Associates Inc. MD (6.28%), Jennison Associates LLC (4.02%), Nuveen Asset Management LLC (1.62%) and Invesco Ltd. (1.46%). Company insiders that own Alexion Pharmaceuticals stock include Ann M Veneman, Aradhana Sarin, Bros Advisors Lp Baker, Christopher J Coughlin, Daniel Bazarko, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.
Which institutional investors are selling Alexion Pharmaceuticals stock?
ALXN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Investec Asset Management LTD, Janus Henderson Group PLC, Janus Henderson Group PLC, AQR Capital Management LLC, Invesco Ltd., Iridian Asset Management LLC CT and Marshall Wace North America L.P.. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.
Which institutional investors are buying Alexion Pharmaceuticals stock?
ALXN stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Renaissance Technologies LLC, Swedbank, Prudential Financial Inc., Vanguard Group Inc., BlackRock Inc., Canada Pension Plan Investment Board and Marshall Wace LLP. View Insider Buying and Selling for Alexion Pharmaceuticals.
How do I buy shares of Alexion Pharmaceuticals?
Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexion Pharmaceuticals' stock price today?
One share of ALXN stock can currently be purchased for approximately $123.49.
How big of a company is Alexion Pharmaceuticals?
Alexion Pharmaceuticals has a market capitalization of $27.69 billion and generates $4.13 billion in revenue each year. The biopharmaceutical company earns $77.60 million in net income (profit) each year or $7.09 on an earnings per share basis. Alexion Pharmaceuticals employs 2,656 workers across the globe.View Additional Information About Alexion Pharmaceuticals.
What is Alexion Pharmaceuticals' official website?
How can I contact Alexion Pharmaceuticals?
Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]
MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
